Cargando…
Increased Efficacy of Brentuximab Vedotin (SGN-35) in Combination with Cytokine-Induced Killer Cells in Lymphoma
Brentuximab vedotin (SGN-35) is an antibody–drug conjugate with a high selectivity against CD30(+) cell lines and more than 300-fold less activity against antigen-negative cells. In the last years, the results of many in vitro and in vivo studies have led to the fast approval of this drug to treat l...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964432/ https://www.ncbi.nlm.nih.gov/pubmed/27376285 http://dx.doi.org/10.3390/ijms17071056 |